Optimizing Benefit/Risk Ratio in Breast Cancer Diagnosis and Radiotherapy: Identifying Molecular, Cellular and Imaging Signatures of Breast Cancer Heterogeneity to Improve Personalized Therapeutic Strategies for Synergistic Treatment Combinations – IMAGEOMICS

Project coordinator

Géza Sáfrány, MD, PhD, DSc, dept. head
National Center for Public Health and Pharmacy, Department of Radiobiology and Radiohygiene

Project partners

European Alliance for Medical Radiation Protection Research
Otto von Guericke University
Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas
Barcelona Institute for Global Health
Italian National Agency for New Technologies, Energy and Sustainable Economic Development
University of Pavia

Project duration

Duration 40 months, start 01/02/2024

Project objectives and goals:

The main aims of IMAGEOMICS are to improve benefit/risk ratio of breast cancer (BC) patients by identifying patients with a predicted favourable response to combined radiotherapy (RT) and immunotherapy and to develop new imaging modality with increased diagnostic potential and reduced ionizing radiation exposure. These aims will be realized through the following specific objectives: a) investigate how RT influences immunogenic heterogeneity of BC cells of different molecular subtypes using in vitro and in vivo approaches; b) test the applicability of nanoparticles for X ray fluorescence computed tomography (XFCT) to be used for the detection of BC heterogeneity; c) to identify local and systemic signatures that predict patient benefit from combined RT and immunotherapy and test their clinical applicability; d) to integrate data retrieved from experimental models and human studies with epidemiological data to build up a protocol for optimal patient stratification.